ArticleJournal of the American Geriatrics Society2026
Assessing Associations of Three Types of Higher-Risk Medication Use and Mortality in Older Adults.
Article in Journal of the American Geriatrics Society, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundHigher-risk medication use-including regimens with polypharmacy, drug-drug interactions (DDIs), and potentially inappropriate medications (PIMs)-has been linked to adverse outcomes in older adults. However, studies establishing associations between higher-risk medication use and mortality have lacked measures of organ function and considered types of higher-risk medication exposures in isolation, allowing potential confounding and overestimation of harm.
methodsWe conducted a prospective cohort study of adults aged ≥ 65 years who took part in the National Health and Nutrition Examination Survey (NHANES) from 1999 to 2016, with mortality follow-up through 2019. Our primary exposures were three types of higher-risk medication use: polypharmacy, DDIs, and PIMs. In primary analyses, these were defined, respectively, as follows: being on ≥ 5 prescription medications (polypharmacy); using two medications with ≥ 1 major DDI; and using ≥ 1 prescription PIM. Exposures were determined by medication review during the baseline survey. The primary outcome was all-cause mortality. Multivariable Cox regression models estimated mortality risk associated with each type of higher-risk medication use, sequentially adjusting for sociodemographic factors and comorbidities, organ function and health behaviors, and patterns of higher-risk medication use.
resultsAmong 7828 eligible participants (representing 26.5 million adults), 54.3% experienced at least one type of higher-risk medication use: 40.0% had polypharmacy, 11.4% had a DDI, and 37.6% used a PIM. In fully adjusted models including all higher-risk medication exposures, only polypharmacy remained significantly associated with increased mortality (hazard ratio [HR] 1.38; 95% CI 1.26-1.51). Sensitivity and subgroup analyses by age and health status yielded generally consistent findings.
conclusionsWhen considering multiple types of higher-risk medication exposure, only polypharmacy was consistently and independently associated with increased mortality among older adults. These results highlight the harms of polypharmacy specifically and could help further target deprescribing interventions to the most high-risk patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.